ClinicalTrials.gg
CompletedNCT04226599DissolveAVFUpdated Feb 11, 2025

A Safety and Efficacy Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With DissolveAV

An interventional study of Dissolve AVF and Armada 35 in Fistulas Arteriovenous, sponsored by DK Medical Technology (Suzhou) Co., Ltd.. Completed at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by DK Medical Technology (Suzhou) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Arteriovenous Fistula with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Arteriovenous Fistula · China.

Enrollment
6th of 14
220 · median 184
Started
2019
with 1 other
No phase
13 of 20
4 open now
Registered
8th of 20
by date
Lead sponsor
2 of 20
DK Medical Technology (Suzhou) Co., Ltd.

Among the 20 studies in Arteriovenous Fistula with a site in China, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 with no phase, and was the 8th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 20 studies in Arteriovenous Fistula with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Arteriovenous Fistula with a site in China, or all of them as a file.
02

Study summary

Drug-coated balloons delivering paclitaxel at the angioplasty site have proved their superiority in the treatment of coronary and peripheral arterial stenoses. Paclitaxel reduces neointimal hyperplasia, therefore, it represents an attractive option for AVF stenoses. This trial is aimed to evaluate the safety and efficacy of Peripheral scoring drug balloon (Dissolve AV) or Balloon Dilatation catheter ( Armada 35) in treating AVF stenosis in chinese population.

Read the detailed description

This is a prospective, multi-center, randomized controlled, open-label, superiority study. A total of 220 subjects will be enrolled from 11 sites in China. All subjects enrolled will be randomly assigned to the test group (Dissolve AV group, n=110) and the control group (Armada 35 group, n=110) with randomized allocation ratio of 1:1. Subjects in the test group and the control group will be treated with Peripheral scoring drug balloon or Balloon Dilatation catheter

03

Conditions studied

  • Fistulas Arteriovenous

Browse trials for

Keywords

  • Dialysis scoring Fistulas
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years (inclusive), male or female;
  2. Patients with mature AVF/AVG and at least one successful hemodialysis session;
  3. Target lesion located in the AVF/AVG reflux vein (excluding the feeding artery and central vein);
  4. With hemodynamically significant AVF/AVG stenosis and meeting two of the following conditions (A \& B) A. ≥ 50% stenosis of the target lesion as assessed by angiography B. Presence of at least one of the following (as defined in the NKF-K/DOQI guidelines) 1)Significantly elevated venous pressure during dialysis 2)Unexplained decrease in dialysis dose 3)Decrease in pump-controlled blood flow;
  5. De novo or restenotic target lesion consisting of one or more tandem lesions, and with a visual reference vessel diameter of 4.0-8.0 mm and a total length ≤ 40 mm for the target lesion;
  6. All non-target lesions must have \<50% stenosis without clinical indication for treatment.
  7. Patients who have signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Patients who are participating in another clinical trial of a drug product or medical device;
  2. Patients previously enrolled in this trial;
  3. Women of childbearing age with a non-negative pregnancy test prior to surgical procedure, or lactating women;
  4. Patients treated with major surgeries (e.g., open-heart surgery, cranial surgery) within 30 days prior to enrollment in the study;
  5. Immature AVF/AVG (not subjected to dialysis; this vascular access has not been subjected to a single successful dialysis due to insufficient inner diameter that prevents successful puncture and results in inadequate blood flow);
  6. Calcified lesions that are not expected to be dilated with a balloon;
  7. AVF/AVG implanted with a stent;
  8. AVF/AVG lesions previously treated with DCB;
  9. Target lesions located at the venous anastomosis of AVF/AVG;
  10. Impaired central venous reflux ;
  11. Presence of a stenotic lesion in the artery that severely interferes with blood flow;
  12. Patients with known allergy or intolerance to paclitaxel or contrast agent;
  13. Patients with a of less than 1 year;
  14. Patients with concomitant systemic lupus erythematosus (SLE), ANCA-associated small vessel vasculitis;
  15. Patients with a history of coagulopathy or thrombocytopenic purpura;
  16. Patients treated with or scheduled to be treated with renal transplant or who have switched to peritoneal dialysis;
  17. Vascular access infections or active systemic infections;
  18. Presence of other medical conditions considered ineligible for the study as assessed by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Dissolve AVF Group

    This group treated with Peripheral scoring drug balloon.Dissolve AVF

    Device: Dissolve AVF

  • Active comparator
    PTA Group

    This group treated with plain balloon catheter.Armada 35

    Device: Armada 35

Interventions

  • DeviceDissolve AVF

    Subjects in the test group will be treated with peripheral scoring drug balloon.

    Also known as: Using Peripheral scoring drug balloon catheter to cover the whole treated segment

  • DeviceArmada 35

    Subjects in the test group will be treated with plain balloon catheter.

    Also known as: Using plain balloon catheter to cover the whole treated segment

06

What researchers measure

Primary outcomes

  1. Target lesion primary patency (TLPP) at 6 months post-procedure

    TLPP ends with postoperative target lesion (including 5 mm proximal and 5 mm distal to the target lesion) failure (TLF) or target lesion-associated vascular access thrombosis. TLF is defined as the presence of at least one clinical symptom of inadequate dialysis blood flow (as defined in the NKF-K/DOQI guidelines) due to stenosis of the target lesion (≥ 50% stenosis of the target lesion on imaging), including significantly elevated venous pressure during dialysis, abnormal physical examination findings, and a decrease in pump-controlled blood flow.

    Time frame: 6 month post-procedure

Secondary outcomes

  1. Target lesion primary patency (TLPP) at 12 months post-procedure

    TLPP ends with postoperative target lesion (including 5 mm proximal and 5 mm distal to the target lesion) failure (TLF) or target lesion-associated vascular access thrombosis. TLF is defined as the presence of at least one clinical symptom of inadequate dialysis blood flow (as defined in the NKF-K/DOQI guidelines) due to stenosis of the target lesion (≥ 50% stenosis of the target lesion on imaging), including significantly elevated venous pressure during dialysis, abnormal physical examination findings, and a decrease in pump-controlled blood flow.

    Time frame: 12 Month post-procedure

  2. Device success

    When evaluated with a single balloon dilatation catheter, it is defined as successful reach of a target lesion, dilatation without rupture, and successful withdrawal.

    Time frame: 0 day post-procedure

  3. Procedural Success

    It is defined as ≤ 30% residual stenosis of the target lesion, and the absence of serious perioperative adverse events.

    Time frame: 0 day post-procedure

  4. Clinical success

    At least one session of successful hemodialysis following the procedure.

    Time frame: 0 - 5 days post-procedure

07

Study locations

10 sites
  • Emergency general hospital
    Beijing, Beijing, China
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
  • Tongren hospital, Capital medical university
    Beijing, Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • ShuGuang Hospital affiliated to Shanghai University of Traditional Chinese
    Shanghai, Shanghai 200000, China
  • Huashan hospital affiliated to FuDan university
    Shanghai, Shanghai, China
  • Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai, China
  • Taiyuan Central Hospital
    Taiyuan, Shanxi, China
  • Shaoyifu hospital, zhejiang medical universiyt
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2021, 26 months.

Of 84 interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 13, 2020
StartActual
Jul 23, 2019
Primary completionActual
Oct 2, 2021
CompletionActual
Jan 4, 2022
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04226599
Lead sponsor
DK Medical Technology (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Jan 13, 2020
Start date
Jul 23, 2019
Primary completion
Oct 2, 2021
Completion
Jan 4, 2022
Last update
Feb 11, 2025

Study contacts

YE CHAOYANG
study chair · ShuGuang Hospital affiliated to Shanghai University of Traditional Chinese

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion